Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ZOMIG

« Back to Dashboard
Zomig is a drug marketed by Astrazeneca and IPR and is included in three NDAs. It is available from five suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ZOMIG is zolmitriptan. There are twenty drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.

Summary for Tradename: ZOMIG

Patents:2
Applicants:2
NDAs:3
Suppliers / Packagers: see list15

Clinical Trials for: ZOMIG

Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
Status: Completed Condition: Migraine

Zomig - Treatment of Acute Migraine Headache in Adolescents
Status: Completed Condition: Migraine Headache

ZAP, US. Zomig for Appropriate for Primary Care
Status: Completed Condition: Migraine

Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
Status: Completed Condition: Migraine

Efficacy and Tolerability of Zolmitriptan Nasal Spray
Status: Completed Condition: Migraine

Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
Status: Active, not recruiting Condition: Migraine

Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine
Status: Completed Condition: Acute Migraine; Migraine Headache; Headache Disorders

Effects of Zolmitriptan on Sensory Transmission After Spinal Cord Injury
Status: Completed Condition: Spinal Cord Injuries; Muscle Spasticity

Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
Status: Completed Condition: Migraine

Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
Status: Completed Condition: Migraine Disorders

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca
ZOMIG
zolmitriptan
SPRAY;NASAL021450-003Sep 16, 2013RXNo7,220,767*PED<disabled>Y<disabled>
Ipr
ZOMIG
zolmitriptan
TABLET;ORAL020768-001Nov 25, 1997RXNo<disabled><disabled>
Astrazeneca
ZOMIG
zolmitriptan
SPRAY;NASAL021450-004Sep 30, 2003RXYes7,220,767*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZOMIG

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca
ZOMIG
zolmitriptan
SPRAY;NASAL021450-004Sep 30, 20035,466,699*PED<disabled>
Ipr
ZOMIG
zolmitriptan
TABLET;ORAL020768-002Nov 25, 19975,863,935*PED<disabled>
Ipr
ZOMIG
zolmitriptan
TABLET;ORAL020768-001Nov 25, 19975,863,935*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ZOMIG

Drugname Dosage Strength RLD Submissiondate
zolmitriptanNasal Spray5 mg/sprayZomig11/14/2013
« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc